Top

Published in:

01-04-2014 | Original paper

Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection

Authors: Rossana Verónica Mendoza López, José Eduardo Levi, José Eluf-Neto, Rosalina Jorge Koifman, Sergio Koifman, Maria Paula Curado, Pedro Michaluart-Junior, David Livingstone Alves Figueiredo, Fabiano Pinto Saggioro, Marcos Brasilino de Carvalho, Luiz Paulo Kowalski, Márcio Abrahão, Francisco de Góis-Filho, Eloiza Helena Tajara, Tim Waterboer, Paolo Boffetta, Paul Brennan, Victor Wünsch-Filho

Published in: Cancer Causes & Control | Issue 4/2014

Abstract

Background

The role of human papillomavirus (HPV) on head and neck squamous cell carcinoma (HNSCC) survival in regions with low HPV prevalence is not yet clear. We evaluated the HPV16 infection on survival of HNSCC Brazilian patient series.

Methods

This cohort comprised 1,093 HNSCC cases recruited from 1998 to 2008 in four Brazilian cities and followed up until June 2009. HPV16 antibodies were analyzed by multiplex Luminex assay. In a subset of 398 fresh frozen or paraffin blocks of HNSCC specimens, we analyzed for HPV16 DNA by L1 generic primer polymerase chain reaction. HNSCC survival according to HPV16 antibodies was evaluated through Kaplan–Meier method and Cox regression.

Results

Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. HPV16 DNA positive in tumor tissue was also higher in the oropharynx. Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. The death risk of oropharyngeal squamous cell carcinoma patients HPV16 E6/E7 antibodies positive was 78 % lower than to those who test negative.

Conclusion

Oropharyngeal squamous cell carcinoma is less aggressive in the HPV16 E6/E7 positive serology patients. HPV16 E6/E7 antibody is a clinically sensible surrogate prognostic marker of oropharyngeal squamous cell carcinoma.

Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371:1695–1709PubMedCrossRef

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 [Internet]. Lyon, France: International Agency for Research on Cancer; [cited 2012 Aug 30]. http://globocan.iarc.fr

Carvalho AL, Ikeda MK, Magrin J, Kowalski LP (2004) Trends of oral and oropharyngeal cancer survival over five decades in 3267 patients treated in a single institution. Oral Oncol 40:71–76PubMedCrossRef

Szymanska K, Hung RJ, Wünsch Filho V, Eluf Neto J, Curado MP, Koifman S et al (2011) Alcohol and tobacco, and the risk of cancers of the upper aerodigestive tract in Latin America: a case–control study. Cancer Causes Control 22:1037–1046PubMedCrossRef

Human papillomaviruses (2007) Lyon, France: International Agency for Research on Cancer- IARC Monograph on the Evaluation of Carcinogenic Risks to Humans

Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P et al (2003) Human papillomavirus and oral cancer: The International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst 95:1772–1783PubMedCrossRef

Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP et al (2006) Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 120:825–832CrossRef

D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956PubMedCrossRef

Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G et al (2009) Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 125:362–366PubMedCrossRef

10.

Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J et al (2011) Low human papillomavirus prevalence in head and neck cancer: results from two large case–control studies in high-incidence regions. Int J Epidemiol 40:489–502PubMedCrossRef

11.

Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H et al (2008) Improved survival of patients with human papillomavirus–positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269PubMedCrossRef

12.

Smith EM, Rubenstein LM, Ritchie JM, Lee JH, Haugen TH, Hamsikova E et al (2008) Does treatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomarkers Prev 17:2087–2096PubMedCrossRef

13.

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCentralPubMedCrossRef

14.

Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI et al (2012) Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res 72:5004–5013PubMedCentralPubMedCrossRef

15.

World Health Organization (1992) International statistical classification of diseases and related health problems. 10th rev. World Health Organization, Washington, DC

16.

Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP et al (2007) Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99:777–789PubMedCrossRef

17.

Sobin LH, Wittekind C (2002) TNM classification of malignant tumours. International Union Against Cancer, 6th edn. Wiley-Liss, New York

18.

Kleter B, Van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, Ter Schegget J et al (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508–2517PubMedCentralPubMed

19.

Coutlée F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N et al (2002) Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 40:902–907PubMedCentralPubMedCrossRef

20.

Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H et al (1994) Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infec Dis 170:1077–1085CrossRef

21.

Sehr P, Zumbach K, Pawlita M (2001) A generic capture ELISA for recombinant proteins fused to glutathione-S-transferase: validation for HPV serology. J Immunol Methods 253:153–162PubMedCrossRef

22.

Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO et al (2005) Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 51:1845–1853PubMedCrossRef

23.

Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, Vaccarella S et al (2007) Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16:1874–1879PubMedCrossRef

24.

Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467–475PubMedCrossRef

25.

Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS (2010) Meta-analysis of the impact of human papillomavirus (HPV) on risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2:15. doi:10.1186/1758-3284-2-15 PubMedCentralPubMedCrossRef

26.

Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP (2010) Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 127:111–117PubMedCrossRef

27.

Rotnáglová E, Tachezy R, Saláková M, Procházka B, Košl’abová E, Veselá E et al (2011) HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. Int J Cancer 129:101–110PubMedCrossRef

28.

Rubenstein LM, Smith EM, Pawlita M, Haugen TH, Hamsikova E, Turek LP (2011) Human papilomavírus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study. Infec Agent Cancer 6:9. doi:10.1186/1750-9378-6-9 CrossRef

29.

Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP (2012) Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol. doi:10.1155./2012/571862 PubMedCentralPubMed

30.

Méndez E (2012) Biomarkers of HPV infection in oropharyngeal carcinomas: can we find simplicity in the puzzle of complexity? Cancer Res 72:4896–4898PubMedCrossRef

Title: Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection
Authors: Rossana Verónica Mendoza López
José Eduardo Levi
José Eluf-Neto
Rosalina Jorge Koifman
Sergio Koifman
Maria Paula Curado
Pedro Michaluart-Junior
David Livingstone Alves Figueiredo
Fabiano Pinto Saggioro
Marcos Brasilino de Carvalho
Luiz Paulo Kowalski
Márcio Abrahão
Francisco de Góis-Filho
Eloiza Helena Tajara
Tim Waterboer
Paolo Boffetta
Paul Brennan
Victor Wünsch-Filho
Publication date: 01-04-2014
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 4/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-014-0348-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States

Bilateral oophorectomy and risk of cancer in African American women

Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes

C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study

The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation

Nutrient-based dietary patterns and prostate cancer risk: a case–control study from Italy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer